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ttp://dx.doi.org/10.1016/j.ajpath.2014.07.012Retinopathy of prematurity adversely affects premature infants because of oxygen-induced damage of
the immature retinal vasculature, resulting in pathological neovascularization (NV). Our pilot studies
using the mouse model of oxygen-induced retinopathy (OIR) showed marked increases in angiogenic
mediators, including endothelins and endothelin receptor (EDNR) A. We hypothesized that activation of
the endothelin system via EDNRA plays a causal role in pathological angiogenesis and up-regulation of
angiogenic mediators, including vascular endothelial growth factor A (VEGFA) in OIR. Mice were
exposed to 75% oxygen from post-natal day P7 to P12, treated with either vehicle or EDNRA antagonist
BQ-123 or EDNRB antagonist BQ-788 on P12, and kept at room air from P12 to P17 (ischemic phase).
RT-PCR analysis revealed increased levels of EDN2 and EDNRA mRNA, and Western blot analysis revealed
increased EDN2 expression during the ischemic phase. EDNRA inhibition signiﬁcantly increased vessel
sprouting, resulting in enhanced physiological angiogenesis and decreased pathological NV, whereas
EDNRB inhibition modestly improved vascular repair. OIR triggered signiﬁcant increases in VEGFA
protein and mRNA for delta-like ligand 4, apelin, angiopoietin-2, and monocyte chemoattractant
protein-1. BQ-123 treatment signiﬁcantly reduced these alterations. EDN2 expression was localized to
retinal glia and pathological NV tufts of the OIR retinas. EDN2 also induced VEGFA protein expression in
cultured astrocytes. In conclusion, inhibition of the EDNRA during OIR suppresses pathological NV and
promotes physiological angiogenesis. (Am J Pathol 2014, 184: 3040e3051; http://dx.doi.org/
10.1016/j.ajpath.2014.07.012)Supported by NIH grants R01-EY11766 and R01-EY04618, the Depart-
ment of Veterans Affairs, Veterans Health Administration, Ofﬁce of
Research and Development, Biomedical Laboratory Research and Devel-
opment grant BX001233, American Heart Association grant 11SDG744008,
and the Culver Vision Discovery Institute at Georgia Regents University.
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Disclosures: None declared.Retinal angiogenesis has been extensively studied, under
both physiological and pathological conditions, to elucidate
the molecular mechanisms governing vessel growth and
development. Pathological angiogenesis is a common hall-
mark of ischemic retinopathies, such as diabetic retinopathy
and retinopathy of prematurity (ROP). Ischemia triggers
hypoxia and improper growth factor production, leading to
molecular changes that disrupt normal vessel growth and
homeostasis, resulting in pathological angiogenesis. In ROP,
which is a leading cause of visual impairment in preterm
infants, the immature retina is exposed to high extrauterine
oxygen, which causes degeneration of the retinal micro-
vessels (vaso-obliteration) and inhibition of normal vascular
development. Thereafter, retinal ischemia occurs, which
leads to compensatory pathological neovascularization (NV)
with sprouting of abnormal vessels from the retina into thestigative Pathology.
.vitreous.1,2 In 2007, 13% of live births in the United States
were reported premature (<37 weeks’ gestation).3 The
oxygen-induced retinopathy (OIR) model of ischemic reti-
nopathy conveniently reproduces the vaso-obliteration and
NV phases of ROP. During the hyperoxic phase of the dis-
ease, production of key growth factors, such as vascular
endothelial growth factor A (VEGFA) and angiopoietins, is
Endothelins in Pathological Angiogenesissuppressed and the developing microvessels regress. In the
subsequent phase of the disease, an imbalanced expression of
these factors results in aberrant growth of new vessels,
leading to pathological NV.4,5 Studies in the OIR mouse
model have demonstrated that retinal ischemia triggers
release of angiogenic mediators, such as VEGFA, which
promotes formation of aberrant leaky vessels. In some cases,
this causes retinal detachment and blindness.2,6,7 Current
therapies include injections of anti-VEGFA agents and laser
photocoagulation,3 but a less invasive and effective therapy is
yet to be developed.
The retinal vasculature grows by radial migration of
endothelial tip cells. Tip cells lead vascular sprouting by
responding to a gradient of VEGFA, produced by the retinal
astrocytes, and other guidance cues in the local environ-
ment.8 Studies indicate that increased pathological NV dur-
ing OIR involves a plethora of angiogenic mediators, such as
VEGFA, erythropoietin,4,5 angiopoietin-2 (ANGPT2),9
apelin (APLN),10 and delta-like ligand 4 (DLL4).11 An
imbalance of these mediators leads to formation of chaotic
vessels, which are often misguided into the vitreous and
cause retinal detachment and blindness. The role of angio-
genic mediators in pathological NV is well established, but
the interplay of such mediators with other vasoactive factors
is largely unknown.
We conducted mRNA analysis using the OIR model and
discovered that expression of endothelins (ETs) and ET
receptors is highly increased during the ischemic phase of
the disease. The ETs are a family of 21eamino acid pep-
tides with three isoforms, EDN1, EDN2, and EDN3. Each
of these is encoded by a different gene and released by
proteolysis of precursor proteins to act in an autocrine or
paracrine manner. All three are distributed widely
throughout various tissues, including kidney, lung, in-
testines, liver, brain, and retina.12e15 ETs can bind to two
distinct G protein-coupled receptors, endothelin receptors
(EDNRs) A and B. EDNRA has a higher afﬁnity for EDN1
and EDN2, whereas EDNRB binds to all three ETs
equally.16 Activation of both receptors is known to mediate
vasoconstriction in vascular smooth muscle cells, whereas
EDNRB activation mediates vasodilation in vascular endo-
thelial cells (EC) via endothelial nitric oxide production.
The importance of the ET system has been demonstrated in
various diseases. Hypoxia up-regulates EDN2, ET re-
ceptors, and VEGFA mRNA expression in a hypoxia-
inducible factor-1aedependent manner in murine and
human breast tumor cell lines.17 Under normal conditions,
astrocytes in the brain express low levels of ETs, but after
ischemia, ETs and their receptors are greatly enhanced.18,19
Retinas from diabetic rats show an increase in mRNA for
EDN1, EDN3, and their receptors.20 Studies in models of
photoreceptor disease/injury have shown that transcripts for
EDN2 and EDNRB are increased and are localized to
photoreceptors and glial cells, respectively.21 These studies
demonstrate that endothelins are involved in pathogenesis of
both vascular and nonvascular diseases.The American Journal of Pathology - ajp.amjpathol.orgRecent work suggests that overexpression of EDN2 in the
mouse neural retina leads to hypoxia, hinders perfusion of
the growing vessels, and limits development of both the
superﬁcial and deep vessels. Moreover, EDN2-dependent
inhibition of angiogenesis in the neural retina is mediated
through EDNRA, but not EDNRB.22 These data suggest
that EDN2 activation of EDNRA plays a signiﬁcant role in
inhibiting angiogenesis in the developing retina. However,
the impact of ETs and their receptors on pathological NV in
ischemic retinopathy is completely unknown.
We, therefore, investigated the role of the endothelin
system in pathological NV. Transcripts of EDN2 and
EDNRA are increased during the ischemic phase of OIR,
and inhibition of EDNRA during OIR promoted physio-
logical angiogenesis and suppressed pathological NV. In
addition, blockade of EDNRA reversed misdirected vessel
growth by enhancing vessel sprouting at the leading edges
of neovessels and reduced ischemia-induced angiogenic
mediators. Neutralizing actions of endothelins through
EDNRA blockade may provide an effective approach to
resolving pathological NV and enhancing vision in patients
with ROP.
Materials and Methods
Treatment of Animals
All procedures with animals were performed in accordance
with The Association for Research in Vision and Ophthal-
mology Statement for the Use of Animals in Ophthalmic and
Vision Research and were approved by the institutional an-
imal care and use committee (Animal Welfare Assurance
number A3307-01). A mouse model of OIR was used as
previously described.6 Brieﬂy, at post-natal day 7 (P7),
C57BL/6 mouse pups, along with nursing mothers, were
placed in 75% oxygen. At P12, they were returned to room air
(RA; 21% oxygen) for 5 days until P17. By using this model
of ischemic retinopathy, obliteration of the retinal vessels is
induced during the exposure to 75% oxygen. Immediately on
return to RA, the avascular central retina becomes hypoxic,
leading to signiﬁcant vitreous NV that peaks at P17.
Intravitreal Injection
P12 mice were anesthetized by i.p. injection of 625 mg/kg
2,2,2-tribromoethanol (Avertin, Sigma-Aldrich, St. Louis,
MO) and local administration of proparacaine HCL
ophthalmic solution (Akorn, Lake Forest, IL) onto the eye.
Intravitreal injections were performed by delivering 1 mL of
vehicle or BQ-123 (EDNRA antagonist; Tocris Biosciences,
Minneapolis, MN) or BQ-788 (EDNRB antagonist; Tocris
Biosciences) into the vitreous space by injecting behind the
limbus. BQ-123 was solubilized in 0.9% saline containing 10
mmol/L NaHCO3 and 1% bovine serum albumin. BQ-788
was solubilized in ethanol and further diluted in 0.9% sa-
line. Previous studies in cats have shown that a single3041
Patel et alinjection of BQ-123 (30 mg/50 mL per eye, 1 mmol/L) or BQ-
788 (33mg/50mLper eye, 1mmol/L) injected into the vitreous
was sufﬁcient to elicit a maximum retinal hemodynamic
response.23,24 We tested several concentrations of both re-
ceptor blockers (BQ-123: 10, 17, and 34 mg/mL per eye; BQ-
788: 1.5, 4.5, and 13.5 mg/mL per eye) to ﬁnd the appropriate
concentrations that would ensure maximum response. We
determined that 17mg/mLper eye of BQ-123 (28mmol/L) and
4.5 mg/mL per eye of BQ-788 (6.8 mmol/L) were optimal for
our studies. We chose to deliver a higher concentration of the
drugs into a much smaller mouse vitreous space compared
with previous studies, to allow for drug loss due to the ﬂuid
leakage from the injection site that often occurs during in-
jections. BQ-123 is a highly selective EDNRA antagonist that
has been shown to have high afﬁnity and efﬁcacy for the re-
ceptor (KDZ 1.18 nmol/L in rat heart tissues), and has shown
promising results in small-scale patient studies.25,26 BQ-788
is also speciﬁc for EDNRB (KD Z 1.98 mmol/L in human
left ventricle).25 Vehicle or receptor antagonists were deliv-
ered using a 35-gauge needle mounted to a 10-mL Hamilton
syringe. The tip of the needle was inserted under the guidance
of a dissecting microscope (Leica Wild M650; Leica, Ban-
nockburn, IL) through the dorsal limbus of the eye. Injections
were performed slowly over 3 minutes.Quantitative Real-Time PCR
Total RNA was isolated using an RNA puriﬁcation kit
(RNAqueous 4PCR; Applied Biosystems, Austin, TX) for
retinal tissue or with reagent (TRIzol; Invitrogen, Grand Is-
land, NY) for cells, according to the manufacturer’s in-
structions. Total RNA was reverse transcribed with M-MLV
Reverse Transcriptase (Invitrogen, Grand Island, NY) to
generate cDNA. Gene expression was determined by real-
time quantitative PCR system (StepOne Plus; Applied Bio-
systems, Grand Island, NY) with Power SYBR Green Master
Mix (Applied Biosystems, Grand Island, NY). Various genes
were studied using primers speciﬁc to their cDNA templates
(Table 1). PCRs were set up to acquire cycle threshold for
each sample, determined as the initial increase in ﬂuores-
cence above background. After the completion of the PCR
cycles, melt curves were generated to check the speciﬁcity of
the amplicons. The relative difference in various geneTable 1 Mouse Primer Sequences
Gene symbol Forward primer sequence
EDN1 50-GACTTTCCAAGGAGCTCCAGAA-
EDN2 50-GTGGTCGCCCCAAGCA-30
EDNRA 50-CCATCGACCCCCTAATTTGG-30
EDNRB 50-GCTAGGCATCATCGGGAACTC-3
DLL4 50-TTTGCTCTCCCAGGGACTCT-30
APLN 50-GCTCTGGCTCTCCTTGACTG-30
ANGPT2 50-ACACCGAGAAGATGGCAGTGT-3
CCL2 50-GGCTCAGCCAGATGCAGTTAA-3
VEGFA 50-TACCTCCACCATGCCAAGTG-30
3042expressions was calculated by the DDCT method using hy-
poxanthine phosphoribosyltransferase as the internal control.
Western Blot Analysis
Retinas or cultured cells were homogenized in a radio-
immunoprecipitation assay lysis buffer (Millipore, Billerica,
MA) supplied with phosphatase inhibitor cocktail (Roche,
Indianapolis, IN), 1 mmol/L phenyl methyl sulfonyl ﬂuo-
ride, and protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO). Protein samples (20 mg) were subjected to 10%
SDS-PAGE. Proteins were transferred onto a nitrocellulose
membrane, and the membrane was blocked (5% milk) and
incubated with primary antibodies against rabbit EDN2
(1:60; Sigma-Aldrich), rabbit VEGFA (1:1000; Abcam,
Cambridge, MA), rabbit p-Y-STAT3 (1:500; Cell Signaling,
Danvers, MA), mouse STAT3 (1:2000; BD Biosciences,
San Jose, CA), and mouse b-tubulin (1:10,000; Sigma-
Aldrich), followed by horseradish peroxidaseeconjugated
secondary antibody (1:2000; GE Healthcare, Pittsburgh,
PA). Immunoreactive proteins were detected using the
chemiluminescence system (GE Healthcare).
Immunostaining of Whole-Mount Retinas
Eyes were enucleated at various time points and ﬁxed in 4%
paraformaldehyde overnight. The cornea, sclera, lens, vitre-
ous, and hyaloid vessels were removed, and radial incisions
were made at four equal intervals of the retina. Retinas were
blocked and permeabilized in phosphate-buffered saline
(PBS) containing 10% goat serum and 1% Triton X-100
(Sigma-Aldrich) for 30 minutes. Retinas were then stained
with Alex594-labeled Griffonia simplicifolia isolectin B4
(1:200; Invitrogen, Carlsbad, CA) overnight at 4C. Retinas
were washed in PBS three times, 20 minutes each. Retinas
were ﬂat mounted in mounting medium (Vectashield; Vector
Laboratories, Burlingame, CA) and examined by ﬂuores-
cence and confocal microscopy. Areas of vaso-obliteration
and vitreoretinal neovascular tufts were quantiﬁed using
ImageJ software version 1.47u (NIH, Bethesda, MD), as
previously described.6 To perform vessel sprouting analysis,
high-magniﬁcation images were acquired and vessel sprouts
were counted as previously described.11Reverse primer sequence
30 50-CAGCTCCGGTGCTGAGTTC-30
50-TCCACATCTTGCCAGTCTTTAACA-30
50-GGGCAATAGCCGTGCATT-30
0 50-TTGCGCATGCACTTGTTCTT-30
50-CTGTGGCAATCACACACTCG-30
50-GGTAGCGCATGCTTCCTTCT-30
0 50-CTCCCGAAGCCCTCTTTGTA-30
0 50-CCTACTCATTGGGATCATCTTGCT-30
50-TCATGGGACTTCTGCTCTCCTT-30
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Eyes were removed, ﬁxed in 4% paraformaldehyde (overnight,
4C), equilibrated in 30%sucrose, and embedded inTissue-Tek
Optimum Cutting Temperature compound (Sakura Finetek,
Torrance, CA). Frozen sections (10 mm thick) were per-
meabilized in 1% Triton X-100 (20 minutes) and blocked in
10% normal goat serum containing 1% bovine serum albumin
(1 hour). Sections were incubated overnight in primary anti-
bodies against rabbit EDN2 (1:60; Sigma-Aldrich), chicken
glialﬁbrillary acidic protein (GFAP; 1:500;Abcam), andbiotin-
labeled isolectin B4 (1:100; Vector Laboratories) (4C), fol-
lowed by reaction with secondary antibodies goat anti-rabbit
(1:400; Molecular Probes, Grand Island, NY), goat anti-
chicken (1:500; Jackson Immunoresearch, West Grove, PA),
and 7-amino-4-methylcoumarin-3-acetic acid-labeled avidin
(1:1000;VectorLaboratories). SectionswerewashedwithPBS,
mounted with mounting medium (Vectashield), and examined
using confocal microscopy.
Primary Astrocyte Culture
Primary mouse astrocytes were isolated and cultured accord-
ing to a published method.27 Brieﬂy, cerebral cortices of 1- to
2-day-old CD-1 mice were mechanically and enzymatically
disrupted. After centrifugation, cells were plated in modiﬁed
Eagle’s medium (Hyclone, Logan, UT), supplemented with 2
mmol/L glutamine, 20 mmol/L glucose, 5% fetal bovine
serum, 5% bovine growth serum, 10% calf serum, 10 ng/mL
epidermal growth factor, and 50 IU/mL penicillin/50 mg/mL
streptomycin (Hyclone) at 2.5 hemispheres per 6-well plate.
This procedure routinely produces conﬂuent monolayers of
protoplasmic-like cells 10 to 12 days after plating.
On reaching conﬂuence, cells were exposed to 8 mmol/L
cytosine arabinoside for 5 to 7 days to eliminate the growth of
rapidly dividing cells, including microglia, macrophages, and
oligodendrocytes. Astrocyte cultures were maintained in
modiﬁed Eagle’s medium supplemented with 5% fetal bovine
serum, 5% bovine growth serum, and 50 IU/mL penicillin/50
mg/mL streptomycin until used for experimentation between
days 28 and 35 in vitro. Cultures were serum starved for 12
hours before the experiment. Astrocyte cultures are routinely
>98% pure, as assessed by immunostaining of the glial-
speciﬁc marker, GFAP. For hypoxia experiments, cell cul-
tures were placed in a 37C humidiﬁed chamber, which was
supplied with 95% N2 and 5% CO2. Astrocytes were either
stimulated with 0.5% hypoxia or kept at RA conditions inside
a 37C humidiﬁed chamber for 24 hours. In separate experi-
ments, cells were stimulated with 100 nmol/L recombinant
EDN2 (Sigma-Aldrich) for a time-course analysis. Cell ly-
sates were collected for RT-PCR and Western blot analysis.
Statistical Analysis
Data are presented as means  SEM. Group differences
were evaluated by using Student’s t-test or one-way analysisThe American Journal of Pathology - ajp.amjpathol.orgof variance, followed by Tukey’s post hoc test for statistical
analysis. P < 0.05 was considered signiﬁcant. Animal
studies were performed in groups of 6 to 18 mice. Tissue
culture studies were performed in groups of four to six
cultures, and each experiment was repeated at least twice.
Results
Endothelin Signaling During OIR
To evaluate the potential impact of endothelins in mediating
the damaging effects seen in OIR, we ﬁrst determined the
presence of endothelin transcripts in the OIR retinas. We
conducted a whole genome microarray analysis of the RA
control and OIR retinas obtained on post-natal day 17 (P17)
and evaluated the angiogenic genes that were highly up-
regulated in OIR compared with RA controls. The results
indicated that EDN2 (42-fold), EDN1 (twofold), and
EDNRA (twofold) receptors were among the many genes
that were increased on P17 (data not shown).
To conﬁrm these ﬁndings and further assess the expres-
sion proﬁle of endothelin system components, we performed
a time-course analysis of mRNA levels of EDN1, EDN2,
EDNRA, and EDNRB starting from the onset of the
ischemic phase (P12) to P17 of RA and OIR retinas using
RT-PCR. Relative mRNA expression of each gene was
quantiﬁed by normalizing it to the expression of internal
control and to its respective RA control and plotted as fold
of each RA control. Our data showed a time-dependent
increase in the transcripts of EDN2, EDN1, and EDNRA
from P12-P17 (Figure 1). EDN2 levels were signiﬁcantly
increased from P13 to P17 (100-fold on P13, 138-fold on
P14, and 130-fold on P17 versus P12), indicative of a sus-
tained increase in the message of EDN2 throughout the
ischemic phase of OIR (Figure 1A). EDN1 levels were
oscillating from P12 to P17, but were increased on P17
compared with P12 to P16 (Figure 1B). In addition,
expression of EDNRA steadily increased from P15 to P17
(0.7-fold on P15, 1.4-fold on P16, and 2.3-fold on P17
versus P12), whereas expression of EDNRB was only
modestly increased from P13 to P17 (Figure 1C).
To ascertain that results from mRNA expression correlate
with functional protein expression of EDN2, we performed
Western blot analysis of EDN2. The results showed that
EDN2 expression is signiﬁcantly induced at both P15 and
P17 (Figure 1, D and E). Altogether, these data suggested
that endothelin signaling is signiﬁcantly increased during
OIR and increased action of endothelins, predominantly via
the EDNRA, could be implicated in the pathogenesis of
OIR.
Role of the Endothelin System in Pathological
Angiogenesis
To investigate the functional role of endothelin signaling
in OIR, we performed intravitreal injections of EDNRA3043
Figure 1 Oxygen-induced retinopathy (OIR) increases endothelins and
endothelin receptor expression. Mice were sacriﬁced at the times indicated,
and EDN2, EDN1, EDNRA, and EDNRB mRNA expression in the whole retina
was determined using RT-PCR. Data were normalized to both the expression
of internal control HPRT and to gene mRNA expression of each RA control
and plotted as fold of RA at each time point. A: Relative mRNA expression
of EDN2 increases time dependently and is sustained throughout ischemic
phase of OIR. B: Relative mRNA expression of EDN1 oscillates during
ischemia, but is signiﬁcantly high on P17 compared with all other time
points. C: Relative mRNA expression of EDNRA increases time dependently
from P15 to P17, whereas EDNRB expression is signiﬁcant at P13 to P14 and
P17 compared with P12. D and E: Relative protein expression of EDN2 is
signiﬁcantly induced during the ischemic phase of OIR at both P15 and
P17. *P < 0.05 versus P12 (n Z 3 retinas; A); *P < 0.05 versus P12,
yP < 0.05 versus P13, and zP < 0.05 versus P12 to P16 (nZ 3 retinas; B);
*P < 0.05 versus P12, yP < 0.05 versus P12 to P14 (n Z 3 retinas; C);
*P < 0.05 versus RA (n Z 3 to 4 retinas; D and E).
Patel et alantagonist BQ-123 (17 mg/mL per eye) and EDNRB
antagonist BQ-788 (4.5 mg/mL per eye) on P12 (immedi-
ately after the hyperoxic vaso-obliterative phase), and pro-
cessed the retinas on P17. The dose concentrations of the
antagonists were chosen on the basis of previous literature
and our pilot experiments. The inhibitors were injected on
P12 to neutralize the actions of EDN2, which was dramat-
ically increased starting at P13 (Figure 1A). We performed
analysis to examine potential effects of BQ-123 on EDN1,
EDN2, and EDNRA mRNA levels on P17. This analysis
showed no signiﬁcant change in their expression, suggesting
that BQ-123 treatment did not modulate mRNA expression
of the endothelins or their receptors.
We performed ﬂat mounting, visualized the blood vessels
using isolectin B4 staining, and observed that blockade of3044EDNRA using BQ-123 signiﬁcantly enhanced the regrowth
of normal vessels into the avascular central retina, compared
with the vehicle control. Conversely, the areas of patho-
logical NV were signiﬁcantly reduced by the BQ-123
treatment (Figure 2, AeC). Inhibition of EDNRB slightly
reduced NV tuft formation and modestly improved vascular
repair, but the latter change was not statistically signiﬁcant
(Figure 2, DeF). These ﬁndings suggest that increased
endothelin signaling, predominantly via EDNRA activation,
limits vascular repair and promotes pathological angiogen-
esis during OIR.
In addition, we further analyzed the hypoxic avascular re-
gions for angiogenic vessel sprouts, which normally lead the
growing vascular plexus toward the avascular regions of the
retina. The OIR retinas treated with vehicle had limited
sprouting into the avascular zone and instead the growing
vessels were composed of misdirected and disorganized NV
tufts. On the contrary, BQ-123etreated retinas showed
increased frequency of healthy sprouting and improved orga-
nization of the vessel network (Figure 3, A and B), which
correlate with the above evidence showing increased vascular
coverage and reduced NV. These ﬁndings demonstrate a
causal role of EDNRA activation in governing pathological
angiogenesis during OIR.
Endothelin Signaling Regulates VEGFA Production and
Other Angiogenic Mediators
To study the molecular signaling associated with EDNRA
activation and pathological angiogenesis, we analyzed pro-
duction of pro-angiogenic mediators. We measured activa-
tion of STAT3 and VEGFA expression in RA control,
vehicle, and BQ-123etreated retinas using Western blot
analysis. EDN1 acts to increase STAT3 activation via
EDNRA in adipocytes.28 During OIR, STAT3 activation
has been shown to be correlated with increased VEGFA
expression and pathological angiogenesis.29 OIR triggered a
signiﬁcant increase in VEGFA production (Figure 4A) and
phosphorylation of STAT3 (Figure 4B) compared with RA
control, which was abrogated by BQ-123 treatment. This
suggests that endothelin signaling via EDNRA mediates
VEGFA production, possibly through STAT3 activation
during OIR.
In addition, we analyzed several genes previously linked to
pathological angiogenesis during OIR. OIR signiﬁcantly
increased mRNA expression of DLL4, APLN, ANGPT2, and
monocyte-chemoattractant protein-1 (CCL2). These were
reduced by blockade of EDNRA, suggesting that EDNRA
activation leads to increased production of pro-angiogenic
mediators (Figure 5). Together, these ﬁndings support our
hypothesis that endothelins play a role in pathological
angiogenesis by increasing production of VEGFA and other
angiogenic molecules. However, blockade of EDNRA
prevents overexuberant angiogenic sprouting by limiting
production of angiogenic mediators and promoting physio-
logical vascular repair.ajp.amjpathol.org - The American Journal of Pathology
Figure 2 Endothelin receptor blockade sup-
presses pathological NV and promotes physiological
angiogenesis. P12 Oxygen-induced retinopathy
(OIR) mice were injected intravitreally with vehicle
(Veh) or BQ-123 (17 mg/mL per eye) and sacriﬁced
on P17. Retinas were dissected, ﬂat mounted, and
stained with isolectin B4 (red, blood vessels), and
images were taken using ﬂuorescent microscope. A:
Treatment of OIR mice with BQ-123 enhances
vascular repair by promoting physiological angio-
genesis (indicated by reduced vessel dropout area
within the white borders) and suppresses patho-
logical NV tuft formation (white arrows). The
vessel dropout area was quantiﬁed using ImageJ
software version 1.47u as percentage of whole
retinal area, normalized to the average of the OIRþ
Veh, and plotted as fold of OIR þ Veh. B: OIR mice
treated with BQ-123 show signiﬁcant reduction in
vessel dropout area compared with vehicle. The
pathological NV tuft formation was measured using
semi-automated thresholding technique in ImageJ
software version 1.47u. The total area of NV tufts
was calculated as percentage of whole retinal area,
normalized to the average of the OIR þ Veh, and
plotted as fold of OIR þ Veh. C: OIR mice treated
with BQ-123 show signiﬁcant reduction in NV tuft
area compared with vehicle. DeF: Treatment of OIR
mice with BQ-788 modestly increases vascular
repair by promoting physiological angiogenesis
(indicated by reduced vessel dropout area within
the yellow borders) and suppresses pathological NV
tuft formation (yellow arrows). Quantiﬁcation
shows modest reduction in vessel dropout area and
a small, but signiﬁcant, reduction in NV tuft area
compared with vehicle. *P < 0.05 versus OIR þ
Veh. nZ 12 retinas, three litters of mice (B and C);
nZ 6 retinas, two litters of mice (E and F). Scale
barZ 500 mm (A and D).
Endothelins in Pathological AngiogenesisEndothelin-2 Is Localized to Retinal Glia and NV Tufts
To localize the expression of endothelin-2, we performed
immunoﬂuorescence staining of frozen sections of P17 RA
and OIR retinas. In the RA control retinas, EDN2 immu-
noreactivity was present in the outer plexiform layer (OPL),
inner nuclear layer, and inner plexiform layer (IPL),
whereas in OIR retinas, it was present in the OPL andThe American Journal of Pathology - ajp.amjpathol.orgstrongly expressed in the ganglion cell layer (GCL)
(Figure 6).
The lack of staining of EDN2 in the IPL of OIR retina can
be attributed to the thinning of retina and IPL that typically
occurs during OIR.30,31 In the GCL and nerve ﬁber layer,
EDN2 had a strong presence within and around the NV
tufts, particularly in reactive astrocytes and possibly in
Müller cell end feet and both in and around ECs, as3045
Figure 3 Endothelin receptor A blockade promotes vessel sprouting in
oxygen-induced retinopathy (OIR) retinas. P12 OIR mice were injected
intravitreally with vehicle (Veh) or BQ-123 (17 mg/mL per eye) and sacri-
ﬁced on P17. Retinas were dissected, ﬂat mounted, and stained with iso-
lectin B4 (red, blood vessels), and images were taken at high magniﬁcation
using confocal microscope. A: Two representative images of retinal vessel
sprouting (white arrowheads) are shown for each group. B: Quantiﬁcation
of number of vessel sprouts reveals that OIR mice treated with BQ-123 show
more vessel sprouting compared with OIR þ Veh. *P < 0.05. nZ 6 retinas,
two litters of mice (B). Scale bar Z 20 mm (A).
Figure 4 Endothelin receptor A blockade prevents oxygen-induced
retinopathy (OIR)-induced increase in VEGFA. P12 OIR mice were injected
intravitreally with vehicle (Veh) or BQ-123 (17 mg/mL per eye) and sacriﬁced
on P17. Retinas were collected and processed for Western blot analysis. VEGFA
(A) and p-STAT3 (B) protein expression is signiﬁcantly increased in OIRþ Veh
group compared with RA control; however, EDNRA blockade prevents such
increase in VEGFA and STAT3 activation. Densitometry analysis reveals sta-
tistical differences between the groups. *P< 0.05 versus RA, yP< 0.05 versus
OIR þ Veh. nZ 6 to 9 retinas, two to three litters of mice (A and B).
Patel et alindicated by its colocalization with retinal glia and blood
vessels (Figure 6, A and B).
In OIR retinas, GFAP immunoreactivity was much stronger
than in the RA control retinas and extended into the inner
layers of the retina as well, suggesting its localization inMüller
cells and astrocytes (Figure 6A). Many of the GFAP-positive
processes were also positive for EDN2, suggesting that EDN2
is expressed in both astrocytes and Müller cells. In addition,
primary cultures of mouse cortical astrocytes exposed to
hypoxia (0.5% oxygen) for 24 hours exhibited a signiﬁcant
increase in mRNA expression of EDN2 compared with nor-
moxia control (Figure 6C), conﬁrming that astrocytes are a
source of EDN2 under hypoxic conditions. Levels of mRNA
for EDN1, EDNRA, and EDNRB were not signiﬁcantly3046changed (data not shown). Increases inVEGFAmRNA served
as a positive control for the experiment, because astrocytes are
a major source of VEGFA in the retina.8
A further study testing the effects of EDN2 on VEGFA
protein levels showed a small, but statistically signiﬁcant,
increase after 24 hours of treatment (Figure 6D). The delay
in onset of this increase suggests that the EDN2 effect is
indirect. The modest increase in VEGFA protein levels in-
dicates that EDN2 is not the predominant driver of hypoxia-
induced increases in VEGFA expression in astrocytes.
These data suggest that EDN2 from the astrocytes may
initiate signaling events on astrocytes in an autocrine
manner or on neighboring cells in a paracrine manner.
Discussion
Therapies for ROP are currently limited to laser photoco-
agulation and anti-VEGFA injections. Both have off-target
effects and are invasive.1 Blockade of VEGFA can affect
survival and function of retinal neurons32 and may impair
retinal development. Therefore, there is a dire need for novel
targets. To our knowledge, the data presented herein provide
the ﬁrst evidence that vasoactive endothelins and theirajp.amjpathol.org - The American Journal of Pathology
Figure 5 Endothelin receptor A blockade prevents
oxygen-induced retinopathy (OIR)-induced increase in
angiogenic mediators. P12 OIR mice were injected intra-
vitreally with vehicle (Veh) or BQ-123 (17 mg/mL per eye) and
sacriﬁced on P17. Retinas were collected and processed for
RT-PCR analysis. OIR induces mRNA expression of DLL4, APLN,
ANGPT2, and CCL2 compared with RA control; however, EDNRA
blockade limits the increase in the angiogenic genes.
*P < 0.05 versus RA, yP < 0.05 versus OIR þ Veh. nZ 6 to 9
retinas, two to three litters of mice.
Endothelins in Pathological Angiogenesisreceptors are involved in pathological angiogenesis during
OIR. Although the function of endothelins has been exten-
sively studied in models of diabetes,33,34 hypertension,35
cancer,36e38 and other diseases, their role during patholog-
ical angiogenesis has not been demonstrated previously.
Herein, we show that expression of EDN2 and EDNRA is
highly increased in a mouse model of OIR and that blockade
of EDNRA reduces pathological NV, promotes physiolog-
ical vascular repair, and reduces expression of angiogenic
mediators, including VEGFA.
Endothelins are classically described as potent vasocon-
strictors that regulate blood pressure and volume homeo-
stasis, but they can act on virtually any cell type in the
body.35 In isolated porcine retinal arterioles, EDN1 stimu-
lation causes vasoconstriction through the activation of
EDNRA, suggesting that endothelins also play a signiﬁcant
role in maintaining retinal homeostasis.39 A recent study by
Rattner et al22 suggests that overexpression of EDN2 in the
neural retina provokes hypoxia and inhibits developmental
angiogenesis via activation of EDNRA and not EDNRB. To
our knowledge, our studies provide the ﬁrst evidence of
endothelin system activation during ischemic retinopathy
and that pathological angiogenesis is reduced predominantly
through inhibition of EDNRA, and not EDNRB, further
extending previous ﬁndings.
EDNRA blockade did not modulate mRNA expression of
EDN1, EDN2, or EDNRA. Blockade of EDNRA function
does not require any effect on EDNRA expression. In some
instances, receptor blockade causes an increase in expres-
sion of the receptor. In addition, blockade of EDNRB using
BQ-788 resulted in modest improvement in OIR-induced
vaso-obliteration and a small, but signiﬁcant, decrease in
NV. Thus, it is possible that activation of EDNRB plays a
modest role in the pathological features. Alternately, with
the high concentrations of the antagonists used in this study,
it is also possible that the EDNRB blocker effects are due,
in part, to inhibition of EDNRA and that the EDNRAThe American Journal of Pathology - ajp.amjpathol.orgblocker might also have had some effect on EDNRB
function. It is well known that EDNRA and EDNRB
act differently and may have antagonistic effects, depend-
ing on their location. In smooth muscle cells, EDNRA
and EDNRB mediate vasoconstriction, proliferation, and
ﬁbrosis, whereas in ECs, EDNRB mediates vasodilation.
EDNRB also appears to serve as a clearance receptor to
regulate plasma concentrations of endothelins.35 It is plau-
sible that blockade of EDNRA may lead to a compensatory
increase in EDNRB and a subsequent reduction in retinal
endothelin levels and signaling. On the other hand,
blockade of EDNRB may lead to a compensatory increase
in EDNRA, leading to elevation in retinal endothelin levels
and inhibition of vascular repair. This phenomenon could
explain the predominance of EDNRA-mediated protection
versus modest EDNRB-mediated protection in the above
ﬁndings.
Our studies clearly illustrate the role of endothelins in
pathological angiogenesis, as indicated by formation of NV
tufts. Previous work has shown that endothelins play a
role in regulating growth of ovarian cancer cell lines and
tumors.40,41 EDN1 induces an angiogenic phenotype in
cultured ECs and stimulates NV in a Matrigel plug assay
in vivo.42 Solid tumors contain regions of hypoxia,
which induces ET expression. Hypoxia-induced increases
in EDN2 expression and signaling have been shown to
promote tumor cell survival during hypoxic stress.17 These
data suggest that endothelins are induced by hypoxia and
could be involved in regulating angiogenesis. Our studies
conﬁrm these ﬁndings in a model of ischemic retinopathy
and demonstrate that activation of the endothelin system via
EDNRA increases pathological NV while reducing physi-
ological angiogenesis.
It is of great interest to determine the cell type(s) respon-
sible for endothelin secretion and its actions. In situ hybrid-
ization studies have shown that EDN1 is expressed in cells of
the human retina, including the retinal pigment epithelium,3047
Figure 6 EDN2 colocalizes in retinal glia and blood vessels in the oxygen-induced retinopathy (OIR) retinas. P17 frozen cross sections (10 mm thick) from
RA and OIR were processed for imaging analysis and reacted with anti-GFAP (marker of retinal glia, including astrocytes and Müller cells, red), anti-EDN2
(green), and isolectin B4 (marker of blood vessels, blue). A: Confocal microscopy reveals that in RA retinas, EDN2 is expressed in the OPL, inner nuclear
layer (INL), and IPL, whereas in OIR retinas, it is strongly expressed in the GCL. Within the GCL, EDN2 is present in retinal glia (yellow) and in blood vessels
(turquoise) (white arrows). B: High-magniﬁcation confocal microscopy of the same region (white boxed areas) reveals a close-up view of EDN2 in the retinal
glia and blood vessels of the NV tufts (white arrows). (Representative images shown, nZ 6 to 9). Primary cortical astrocytes from mouse were serum starved
for 12 hours and cultured in normoxia (21% oxygen) and hypoxia (0.5% oxygen) for 24 hours at 37C. RNA from the cells was extracted using the TRIzol
reagent and processed for RT-PCR analysis. C: Hypoxia signiﬁcantly increases mRNA expression of EDN2 and VEGFA in cortical astrocytes compared to normoxia
controls. D: Stimulation of astrocytes with 100 nmol/L EDN2 induces time-dependent changes in the VEGFA protein levels and signiﬁcant increase at 24 hours
after treatment compared with zero-time point. *P < 0.05 versus normoxia (nZ 4, two independent experiments; C); *P < 0.05 versus baseline (nZ 4; D).
Scale bar Z 20 mm (A and B). ONL, outer nuclear layer.
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Endothelins in Pathological Angiogenesisphotoreceptors, IPL, GCL, and astrocytes.43 Various stimuli,
such as increased intraocular pressure in models of glaucoma,
hypoxia in models of brain ischemia, and tumor necrosis
factor (TNF)-a in various retinal disease models, have been
shown to induce EDN1 release from astrocytes, and this has
been implicated in astrogliosis.44 Studies have shown that
endothelins are up-regulated in injured or diseased photore-
ceptors. Light-induced degeneration of photoreceptors leads
to increases in EDN1, EDNRA, and EDNRB in the retinal
pigment epithelium and astrocytes.45 In a mouse model of
retinal photoreceptor degeneration, expression of EDN2,
along with other stress response genes, was highly
increased.46 In addition, studies in models of photoreceptor
disease/injury have shown that EDN2 transcripts are
increased in photoreceptors. It serves as a general stress
signal and activates EDNRB on neighboring Müller cells,
which increase EDNRB expression in response to increased
EDN2 levels.21 In our studies, we also observed a dramatic
increase in EDN2 transcripts and a modest increase in
EDNRB transcript levels in OIR conditions.
Rattner et al22 recently showed that EDN2 acting on
EDNRA, but not EDNRB, on retinal neurons and/or glia
induces hypoxia and production of one or more factors that
arrest migration of the developing vasculature. Their studies
suggest that paracrine or autocrine signaling of endothelins
must limit their diffusion and that local action of endothelins
must take place in the close proximity with retinal neurons
and ECs. We are showing that transcripts of EDN2 are
highly increased in OIR and expression of EDN2 is local-
ized to retinal glia and hypertrophic blood vessels or NV
tufts. From previous studies described above and on the
basis of our data, it can be projected that EDN2 is produced
by retinal glia and ECs in NV tufts within the hypoxic re-
gions of the retina and activates signaling events in these
cells. The same cells then may produce factor(s) that are
ultimately responsible for pathological angiogenesis during
OIR. In addition, the presence of EDN2 in the tufts implies
that EDN2 may directly regulate formation of abnormal
vessels, inhibit physiological angiogenesis, and play a
causal role in pathological angiogenesis.
To further conﬁrm the localization of EDN2, we showed
through cell culture that hypoxia increases EDN2 mRNA in
primary cortical astrocytes from mice. We measured mRNA
expression of EDN1, EDNRA, and EDNRB in cultured
astrocytes and found no signiﬁcant differences between
normoxic and hypoxic astrocytes. Although EDN1 mRNA
levels did not change, it is possible that EDN1 protein
released into the media is increased. A previous study has
shown that TNF-aemediated EDN1 synthesis and release
from human optic nerve head astrocytes are augmented after
hypoxia.47 However, there was no difference in basal
release of EDN1 in control cells exposed to normoxia or
hypoxia. This study suggests that TNF-a is required to
enhance release of EDN1 from astrocytes. Future studies are
needed to investigate the direct or indirect contributions by
EDN1 or EDN2 in retinal glia cells.The American Journal of Pathology - ajp.amjpathol.orgOur studies also revealed that hypoxia increases VEGFA
mRNA in astrocytes. In addition, EDN2 stimulation modestly
increased VEGFA protein expression in astrocytes. Thus, it is
likely that EDN2 produced by hypoxic stimulation of astro-
cytes contributes to the hypoxia-induced increase in VEGFA
mRNA. However, EDN2 is only one of the many factors that
could directly or indirectly inﬂuence VEGFA production
during hypoxia. Moreover, in our studies, the 24-hour delay in
onset of the VEGFA protein increase after EDN2 treatment
strongly suggests an indirect effect involving activation of
other factors. Therefore, the involvement of EDNRA activa-
tion in hypoxia-induced VEGFA production could be minimal
or small. There are other potential sources of VEGFA in the
retina in addition to astrocytes, including theMüller cells48 and
ganglion cells.49,50 Altogether, it is possible that endothelins
indirectly control VEGFA expression through an unknown
factor and, therefore, we observed secondary effects of endo-
thelins in our in vitro and in vivo studies. In our in vivo studies,
EDNRA blockade effects on VEGFA may be indirect due to
enhanced vascular repair and recovery of normal vascular
function, which would reduce relative hypoxia and normalize
VEGFA levels.
More important, our analysis showed that EDN2 mRNA
and protein were highly increased during the ischemic phase
of OIR. This strengthens support for EDN2-induced acti-
vation of EDNRA. Nevertheless, EDN1 mRNA expression
was also increased, and the blockers we used do not
discriminate between EDN1 and EDN2. Thus, we do not
discount the role of EDN1-induced activation of EDNRA.
On the basis of the literature, EDN1 and EDN2 have nearly
the same afﬁnity for EDNRA,35 suggesting that activation
of EDNRA by EDN1 or EDN2 may contribute to the
observed pathological effects.
The mechanisms by which EDN2 modulates pathological
angiogenesis in OIR are not yet clear, but appear to involve
regulation of the angiogenic mediators. Previous study in-
dicates that overexpression of EDN2 leads to increased
production of VEGFA, ANGPT2, DLL4, and APLN tran-
scripts in the superﬁcial layer of the developing retina via
activation of EDNRA. Consequently, this leads to inhibition
of physiological angiogenesis, localized increases in
vascular sprouting, and overgrowth of hypoxic, misguided,
and nonperfused vessels.22 Such vessels are morphologi-
cally similar to NV tufts observed during pathological
angiogenesis. We ﬁnd that in a disease model, ischemia-
induced endothelin system activation via EDNRA leads to
increased production of VEGFA protein and ANGPT2,
DLL4, APLN, and CCL2 transcripts. These changes are
correlated with increased pathological NV, due to localized
overgrowth of immature and misdirected vessels, and
decreased physiological angiogenesis, due to reduced vessel
sprouting into the zone of vascular repair. Studies suggest
that the above alterations can be attributed to disruption of
the balance of signaling molecules, such as DLL4, APLN,
and ANGPT2. DLL4 is induced by VEGFA as a negative
regulator of vascular sprouting. Attenuation of its signaling3049
Patel et alduring OIR enhances angiogenic sprouting, promotes rapid
regrowth of vessels into the hypoxic regions, and reduces
pathological NV.11 In addition, it has been shown that
APLN knockdown during OIR prevents NV and promotes
maturation of ECs by recruiting pericytes.10 ANGPT2 sen-
sitizes retinal vessels to VEGFA and causes NV.51 More-
over, ANGPT2 is expressed in NV tufts under hypoxia, and
its heterozygous deletion abrogates pathological NV during
OIR.52 Therefore, it can be inferred that OIR-induced
VEGFA up-regulates DLL4, which leads to inhibition of
angiogenic sprouting. In addition, OIR-induced APLN and
ANGPT2 are responsible for pathological NV and mis-
directed vascular growth. Our studies show that blockade of
the EDNRA-normalized VEGFA protein, along with DLL4,
APLN, and ANGPT2 transcripts, enhanced angiogenic
sprouting and reduced NV. Collectively, our studies illus-
trate that critical signaling events that govern vessel matu-
ration and physiological angiogenesis were restored through
blockade of EDNRA activation. This further supports our
hypothesis that the endothelin system plays a critical role in
pathological angiogenesis in OIR by modulating production
of angiogenic mediators.
Our study shows that endothelin signaling contributes to
pathological angiogenesis. This work has taken the next step
in identifying EDN2 as a target and a player that has an
inﬂuence on angiogenic mediators, such as VEGFA, DLL4,
and APLN, during OIR. It also builds on previous ﬁndings
and sets forth a new concept that key factors upstream and
downstream of VEGFA play a crucial role in determining
the outcome of angiogenesis. We can conclude from our
data that in ischemic retinopathies, endothelins, predomi-
nantly via activation of EDNRA, inﬂuence VEGFA pro-
duction, which increases DLL4, ANGPT2, and APLN
expression and inhibits directional vessel sprouting. These
actions further increase tissue hypoxia, leading to formation
of NV tufts and inhibition of physiological angiogenesis. To
better understand the mechanism of actions of endothelins,
future studies should investigate the direct role of EDN1 or
EDN2 using tissue-speciﬁc expression of endothelins and
their receptors in models of ischemic retinopathies.Acknowledgments
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